OMNI BIO PHARMACEUTICAL, INC.: 10-Q filed 2013-08-14

Name: OMNI BIO PHARMACEUTICAL, INC.: 10-Q filed 2013-08-14
Creator: OMNI BIO PHARMACEUTICAL, INC.
License: https://creativecommons.org/licenses/by/4.0/

What OMNI BIO PHARMACEUTICAL, INC. reported in its quarterly report filed 2013-08-14 (fiscal Q1 2013): 25 published measures, 63 facts as tagged in accession 0001437749-13-010718.

This filing

Form: 10-Q (quarterly report)
Filed: 2013-08-14
Fiscal period: fiscal Q1 2013
Accession: 0001437749-13-010718 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All OMNI BIO PHARMACEUTICAL, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2013-06-30	1,675,718	USD
At 2013-03-31	699,051	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2013-06-30	1,396,689	USD
At 2013-03-31	1,303,707	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2013-06-30	279,029	USD
At 2013-03-31	-604,656	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2013-06-30	1,261,801	USD
At 2013-03-31	343,279	USD
At 2012-06-30	1,122,783	USD
At 2012-03-31	133,120	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	-681,054	USD	91
2006-02-28 to 2013-06-30	-44,696,006	USD	2680
2012-04-01 to 2012-06-30	-1,131,620	USD	91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	-442,876	USD	91
2006-02-28 to 2013-06-30	-8,898,633	USD	2680
2012-04-01 to 2012-06-30	-422,557	USD	91

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2006-02-28 to 2013-06-30	7,423	USD	2680

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	1,361,398	USD	91
2006-02-28 to 2013-06-30	11,722,662	USD	2680
2012-04-01 to 2012-06-30	912,220	USD	91

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2006-02-28 to 2013-06-30	-1,562,228	USD	2680
2012-04-01 to 2012-06-30	500,000	USD	91

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	203,341	USD	91
2006-02-28 to 2013-06-30	21,622,635	USD	2680
2012-04-01 to 2012-06-30	876,307	USD	91

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	-531,026	USD	91
2006-02-28 to 2013-06-30	-36,959,646	USD	2680
2012-04-01 to 2012-06-30	-1,142,718	USD	91

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2013-06-30	1,389,855	USD
At 2013-03-31	384,991	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2013-06-30	93,162	USD
At 2013-03-31	123,512	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2013-06-30	10,997	USD
At 2013-03-31	42,512	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	531,026	USD	91
2006-02-28 to 2013-06-30	36,959,646	USD	2680
2012-04-01 to 2012-06-30	1,142,718	USD	91

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	27,838	USD	91
2006-02-28 to 2013-06-30	2,433,671	USD	2680
2012-04-01 to 2012-06-30	22,278	USD	91

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2013-06-30	38,178,554	shares
At 2013-03-31	32,018,554	shares

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

Period	Value	Unit	Days
At 2013-06-30	67,178	USD
At 2013-03-31	68,407	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2013-06-30	82,165	USD
At 2013-03-31	81,000	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	-681,054	USD	91
2006-02-28 to 2013-06-30	-44,696,006	USD	2680
2012-04-01 to 2012-06-30	-1,131,620	USD	91

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	503,188	USD	91
2006-02-28 to 2013-06-30	28,146,755	USD	2680
2012-04-01 to 2012-06-30	1,120,440	USD	91

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	1,229	USD	91
2006-02-28 to 2013-06-30	48,853	USD	2680
2012-04-01 to 2012-06-30	838	USD	91

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	-150,028	USD	91
2006-02-28 to 2013-06-30	-7,736,360	USD	2680
2012-04-01 to 2012-06-30	11,098	USD	91

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	1,361,398	USD	91
2006-02-28 to 2013-06-30	9,091,213	USD	2680

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	-31,515	USD	91
2006-02-28 to 2013-06-30	217,174	USD	2680
2012-04-01 to 2012-06-30	-32,800	USD	91

Inspect the source

Entity: OMNI BIO PHARMACEUTICAL, INC. / CIK 0001389870
Captured: 2026-09-23 02:52 UTC
SEC response SHA-256: b9b3aba6d21aa6d13f2cc53a72b3619a8dce8e5c14df68ddd1351a61e50303b7

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001389870.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))